SLC5A2 and diabetes mellitus: Sodium glucose cotransport-2 inhibitors (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptors agonists have shown efficacy in improving diabetes management and cardiovascular outcomes (3, 31).